Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
Researchers at University of Miami, Department of Dermatology target life sciences
May 18th, 2008
Researchers detail in 'Poly-L-lactic acid for the treatment of trauma-induced facial lipoatrophy and asymmetry,' new data in life sciences. "Poly-L-lactic acid (PLLA) is approved by the US Food and Drug Administration (FDA) for the treatment of human immunodeficiency virus (HIV)-associated lipoatrophy. Over the past several years, PLLA has been increasingly used as a treatment for lipoatrophy secondary to the natural process of aging," researchers in the United States report. "There have been no reports on the use of PLLA for trauma-induced facial lipoatrophy and asymmetry. In this article, we review the safety, effectiveness, treatment guidelines, mechanism of action,...
Source: Medical Letter on the CDC & FDA (2008-05-18)
|
